World-First Gene Therapy Enters Human Trials for Age-Related Vision Loss as Scientists Flag High Risk
Updated
Updated · ScienceAlert · Jun 13
World-First Gene Therapy Enters Human Trials for Age-Related Vision Loss as Scientists Flag High Risk
3 articles · Updated · ScienceAlert · Jun 13
Summary
A first-in-human gene therapy aimed at reversing age-related vision loss has entered clinical trials, marking what researchers describe as a world first for the field.
The treatment is designed to make cells "young again" to restore some lost vision, a goal that has made the study one of the year's most closely watched longevity-related trials.
Scientists are split over its prospects: supporters call it a potentially pivotal moment for longevity research, while critics say the approach is extraordinarily high-risk and may not work at all.
The trial now becomes an early test of whether aggressive anti-aging gene therapies can move from theory into human medicine despite substantial safety concerns.
A new gene therapy trial aims to reverse blindness, but how do scientists prevent the revolutionary treatment from creating cancerous cells instead?
Psilocybin temporarily reversed a patient's dementia, but could this 'miracle' be a dangerous fluke that offers more false hope than real treatment?
A dog-sized scorpion dominated ancient land, so why do scientists now believe this apex predator was also returning to the water?
Life Biosciences’ ER-100 Trial: FDA-Approved Gene Therapy Targets Cellular Aging and Vision Loss in 2026
Overview
Life Biosciences has received FDA approval to begin a clinical trial for ER-100, a groundbreaking gene therapy that uses partial epigenetic reprogramming to try to reverse cellular aging. This marks a major milestone for both the company and the field of aging biology, as it is the first time such a therapy will be tested in humans. The trial is supported by recent financing and aims to deliver disease-modifying solutions for patients. By restoring lost epigenetic information in cells, ER-100 seeks to address the underlying causes of aging, building on research that suggests this loss is a key driver of age-related decline.